ERDERA scientific coordinator Daria Julkowska highlights goals for rare disease research in Europe

blank

In a recent interview with Science Business, ERDERA Scientific Coordinator Daria Julkowska discussed the upcoming launch of the European Rare Diseases Research Alliance (ERDERA), its mission, and its critical role in advancing rare disease research across Europe.

This partnership, funded under Horizon Europe, is set to revolutionize the field of rare diseases with a seven-year budget of €380 million.

The partnership will launch its first funding calls in December 2024, as part of its mission to improve rare disease prevention, diagnosis, and treatment. Julkowska emphasized the need for a collaborative European approach, explaining, “For many rare diseases, the number of patients in any one country is often too small to support significance research. Therefore, strong collaboration is essential.”

ERDERA aims to accelerate diagnostic times, develop treatments, and improve the quality of life for Europe’s 30 million rare disease patients. It builds on more than 20 years of EU efforts in rare disease research, including the European Joint Programme on Rare Diseases (EJP RD).

Read the full interview on Science Business here.

This article is part of ERDERA’s ongoing efforts to communicate and engage with stakeholders across Europe and beyond, ensuring the success of this vital initiative.

News & Updates

You might also be interested in

30 million people in Europe live with a rare disease. Yet most still lack a diagnosis or treatment. So what is ERDERA doing about it?
ERDERA will launch its Clinical Trial Call 2026 (ECTC) on 1 July 2026, supporting multinational, GCP‑compliant early‑phase interventional clinical trials in rare diseases.
Pre-announcement describing scope, eligibility and indicative timeline for the ERDERA Clinical Trial Call 2026, expected to open on 1 July 2026.
Budget example showing low and high cost ranges for a Phase 1 rare disease clinical trial with twenty subjects.